ZHAOKE OPHTH-B(06622),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06622 ZHAOKE OPHTH-B

Not Yet Opened 09-23 16:08:13

2.465

-0.045

-1.79%

High2.470	Low2.465	Vol210.50K
Open2.470	D1 Closing2.510	Amplitude0.20%
Mkt Cap1.35B	Tradable Cap1.35B	Total Shares549.00M
T/O519.24K	T/O Rate0.04%	Tradable Shares549.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06622","market":"HK","secType":"STK","nameCN":"ZHAOKE OPHTH-B","latestPrice":2.465,"timestamp":1790150893040,"preClose":2.51,"halted":0,"volume":210500,"delay":0,"changeRate":-0.017928286852589615,"floatShares":549000000,"shares":549000000,"eps":-0.4465463971198419,"marketStatus":"Not Yet Opened","change":-0.045,"latestTime":"09-23 16:08:13","open":2.47,"high":2.47,"low":2.465,"amount":519240,"amplitude":0.001992,"askPrice":2.47,"askSize":10000,"bidPrice":2.46,"bidSize":2500,"shortable":0,"etf":0,"ttmEps":-0.4585089639117442,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790213400000},"marketStatusCode":0,"adr":0,"listingDate":1619625600000,"exchange":"SEHK","adjPreClose":2.51,"openAndCloseTimeList":[[1790127000000,1790136000000],[1790139600000,1790150400000]],"volumeRatio":1.4467353948907076,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06622/wiki","defaultTab":"wiki","newsList":[{"id":"1183555429","title":"Lee's Pharm Secures Exclusive Rights to Develop and Market Novel PARP1 Inhibitor Across Greater China and Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=1183555429","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183555429?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:40","pubTimestamp":1788964828,"startTime":"0","endTime":"0","summary":"Lee's Pharm (00950) has announced that its wholly-owned subsidiary, Lee's Pharm (Hong Kong) Limited, has entered into an exclusive licensing agreement with US-based biotechnology firm 1cBio, Inc. to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1583","BK1587","BK1191","BK1574","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173977599","title":"Zhaoke Ophthalmology’s YUVEZZI™ Hits Primary Endpoint in China Phase II Presbyopia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1173977599","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173977599?lang=en_us&edition=fundamental","pubTime":"2026-09-04 18:41","pubTimestamp":1788518510,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology Limited announced that its innovative eye-drop therapy, YUVEZZI™ (a fixed-dose combination of carbachol and brimonidine tartrate), achieved the prespecified primary endpoint in a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664336546","title":"Zhaoke Ophthalmology Says Presbyopia Eye Drop Yuvezzi Meets Primary Endpoint in China Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664336546","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664336546?lang=en_us&edition=fundamental","pubTime":"2026-09-04 18:39","pubTimestamp":1788518398,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology says presbyopia eye drop YUVEZZI meets primary endpoint in China Phase II trialZhaoke Ophthalmology reported its YUVEZZI presbyopia eye drop met the primary endpoint in a China Ph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL5kNMcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06622","BK1583","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077162","title":"China's Angelalign H1 Revenue Rises on Higher Clear Aligner Case Volume","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077162","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077162?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:13","pubTimestamp":1788174790,"startTime":"0","endTime":"0","summary":"China's Angelalign H1 revenue rises on higher clear aligner case volumeOverviewChina clear aligner maker's H1 2026 revenue rose 42.9% yr/yrAdjusted net profit for H1 2026 grew 79.5% yr/yrCompany attri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1191","BK1593","BK1574","06609","BK1100","BK1583","01477","06699","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663437071","title":"Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2663437071","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663437071?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:00","pubTimestamp":1788170409,"startTime":"0","endTime":"0","summary":"Hong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product salesOverviewHong Kong pharma maker's interim revenue grew 14.6% yr/yr for six months ended June 2026Net income attributable t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1191","00570","BK1606","01477","BK1574","BK1583","06622","00950","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121505356","title":"Lee's Pharm Reports 41.4% Profit Surge in H1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1121505356","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121505356?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:54","pubTimestamp":1788170056,"startTime":"0","endTime":"0","summary":"LEE'S PHARM (00950) has announced its interim results for 2026, posting a revenue of approximately HK$797 million, marking a year-on-year increase of 14.6%.The company recorded a profit attributable...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00950","BK1587","BK1583","06622","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663928076","title":"China's HeartCare Medical H1 Revenue Surges on Stroke Segment Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2663928076","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663928076?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:14","pubTimestamp":1788167685,"startTime":"0","endTime":"0","summary":"China's HeartCare Medical H1 revenue surges on stroke segment growthOverviewChina medical device maker's H1 revenue rose 56.9% yr/yr to RMB291 mlnNet profit attributable to shareholders grew 18.5% yr/","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S09G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0183","06622","BK0097","BK0113","BK0188","BK1606","01477","BK1515","06609","BK1574","01666","BK1100","BK0239","BK1191","LU1688375341.USD","BK0012","600085","BK1587","BK0196","BK1583","BK0086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663266430","title":"Zhaoke Ophthalmology (SEHK:6622) Stock Carries A 34.7x P/S Under Heavy Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663266430","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663266430?lang=en_us&edition=fundamental","pubTime":"2026-08-31 06:36","pubTimestamp":1788129366,"startTime":"0","endTime":"0","summary":"Traders kept Zhaoke Ophthalmology almost flat coming into the H1 2026 report, with the stock up only about 2% over the past week. The calm price action contrasts with a much more charged reality. The company is still posting heavy losses, with H1 basic earnings per share at a loss of ¥0.22 and a net loss of ¥122.6 million.\nThe key issue is valuation. Zhaoke Ophthalmology trades on a P/S multiple of 34.7x, compared with the Hong Kong pharmaceuticals average near 2x. This puts every line of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6622/zhaoke-ophthalmology-shares/news/zhaoke-ophthalmology-sehk6622-stock-carries-a-347x-ps-under","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6622/zhaoke-ophthalmology-shares/news/zhaoke-ophthalmology-sehk6622-stock-carries-a-347x-ps-under","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","BK1583","06622","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143245213","title":"Zhaoke Ophthalmology's Half-Year Results: Net Loss Widens to RMB 123 Million Amid Rising Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=1143245213","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143245213?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:53","pubTimestamp":1787928836,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology-B (06622) has released its interim results for the 2026 fiscal year, showing total revenue of RMB 18.828 million, a year-on-year increase of 19.14%. However, the company recorded...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1587","BK1191","BK1574","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099200","title":"China's Ocumension Therapeutics H1 Revenue Surges on Higher Ophthalmic Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099200","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662099200?lang=en_us&edition=fundamental","pubTime":"2026-08-28 22:24","pubTimestamp":1787927067,"startTime":"0","endTime":"0","summary":"China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product salesOverviewChina ophthalmic pharma firm's half-year revenue rose 44.1% yr/yr to RMB423.7 mlnAdjusted net loss narrowed ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1209","02219","01477","BK1191","BK1587","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662951720","title":"China's Zhaoke Ophthalmology H1 Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2662951720","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662951720?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:24","pubTimestamp":1787923484,"startTime":"0","endTime":"0","summary":"China's Zhaoke Ophthalmology H1 revenue risesOverviewChina ophthalmic drug maker's interim revenue rose yr/yr to RMB 18.8 mlnNon-HKFRS adjusted loss for the period widened slightly to RMB 116.1 mlnCom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1161","06622","BK1583","BK1589","BK1574","02219","02616","BK1209","BK1587","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662696095","title":"Zhaoke Ophthalmology FY26 H1 Loss Widens to RMB 122.59 Million; Revenue Rises 19.14% to RMB 18.83 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662696095","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662696095?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:16","pubTimestamp":1787923002,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology FY26 H1 loss widens to RMB 122.59 million; revenue rises 19.14% to RMB 18.83 millionZhaoke Ophthalmology posted revenue of RMB 18.83 million, up 19.14% for the six months ended Ju","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL4x0NrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","06622","BK1191","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184470015","title":"Lee's Pharmaceutical Flags Higher Interim Profit as Revenue and Margins Improve","url":"https://stock-news.laohu8.com/highlight/detail?id=1184470015","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184470015?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:28","pubTimestamp":1787750895,"startTime":"0","endTime":"0","summary":"Lee's Pharmaceutical Holdings Ltd (00950) has issued a positive profit alert, indicating that the group expects to report an audited net profit attributable to shareholders of between approximately...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1587","00950","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175293354","title":"Hong Kong Stock Movers: Lee's Pharm Surges Over 7% After ZK2401 IND Accepted by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1175293354","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175293354?lang=en_us&edition=fundamental","pubTime":"2026-08-14 15:40","pubTimestamp":1786693226,"startTime":"0","endTime":"0","summary":"LEE'S PHARM (HKEX: 00950) shares surged more than 7%, trading at HK$1.18 as of press time, representing a 7.27% gain with a turnover of HK$2.0132 million.On the news front, the company recently...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","00950","BK4588","BK1574","BK1587","BMED","KCAI","BK1583","06622","BK4585","VXUS","IBBJ","MDTX","BK1191","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165175775","title":"Zhaoke Ophthalmology Enters 5-Year Exclusive Mainland China Distribution Agreement with Pharmentum Biopharma for Epinastine Eye Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=1165175775","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165175775?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:08","pubTimestamp":1786525711,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology Limited has signed an Exclusive Distribution and Promotion Agreement with Pharmentum Biopharma (Beijing) Co., Ltd. to commercialize Epinastine Hydrochloride Eye Drops across...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978528","title":"Zhaoke Ophthalmology Signs Exclusive Distribution Deal with Pharmentum Biopharma for Epinastine Eye Drops in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978528","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658978528?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:55","pubTimestamp":1786524908,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology signs exclusive distribution deal with Pharmentum Biopharma for epinastine eye drops in ChinaZhaoke Ophthalmology entered a five-year exclusive distribution and promotion deal wit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4MYV5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","06622","BK1191","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978534","title":"Zhaoke Ophthalmology - Enters Exclusive Distribution Agreement with Pharmentum Biopharma in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978534","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658978534?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:54","pubTimestamp":1786524877,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490PQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","06622","BK1574","BK1587","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658785379","title":"Zhaoke Ophthalmology - Agreement to Commercialize Epinastine Hydrochloride Eye Drops in China (Excluding Hong Kong, Macau and Taiwan)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658785379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658785379?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:54","pubTimestamp":1786524877,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490PQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1583","06622","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160026165","title":"Zhaoke Ophthalmology: No Change in Issued Shares for July 2026; 66.50 k Shares Await Cancellation After Buy-back","url":"https://stock-news.laohu8.com/highlight/detail?id=1160026165","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160026165?lang=en_us&edition=fundamental","pubTime":"2026-08-03 14:04","pubTimestamp":1785737075,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology Limited (Hong Kong, 06622) filed its Monthly Return for the period ended 31 July 2026, confirming stable capital metrics and ongoing share buy-back activity. Key Takeaways 1....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142554659","title":"Zhaoke Ophthalmology secures Macau clearance for innovative presbyopia therapy YUVEZZI™","url":"https://stock-news.laohu8.com/highlight/detail?id=1142554659","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142554659?lang=en_us&edition=fundamental","pubTime":"2026-07-20 12:22","pubTimestamp":1784521343,"startTime":"0","endTime":"0","summary":"On 20 July 2026, Zhaoke Ophthalmology announced that its fixed-dose, once-daily eye-drop YUVEZZI™ (carbachol 2.75% + brimonidine tartrate 0.1%) obtained marketing approval from the Pharmaceutical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0218},{"period":"3month","weight":-0.01},{"period":"6month","weight":-0.1529},{"period":"1year","weight":-0.3265},{"period":"ytd","weight":-0.1672}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0761},{"period":"6month","weight":-0.0047},{"period":"1year","weight":-0.0507},{"period":"ytd","weight":-0.0311}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Zhaoke Ophthalmology Ltd is an investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs and products. The product pipelines primarily include NVK002 (Atropine) for myopia, CsA Ophthalmic Gel for DED and TAB014 (Bevacizumab) for wAMD. The products are primarily uses to treat eye diseases across both the front and the back of the eye, including dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), glaucoma and corneal epithelial dysfunction (CED). The Company conducts its business in the domestic market and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.147188},{"month":2,"riseRate":0.2,"avgChangeRate":-0.134185},{"month":3,"riseRate":0.2,"avgChangeRate":-0.040318},{"month":4,"riseRate":0.2,"avgChangeRate":0.019445},{"month":5,"riseRate":0.333333,"avgChangeRate":0.015956},{"month":6,"riseRate":0.166667,"avgChangeRate":0.033584},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.047805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.009984},{"month":9,"riseRate":0.5,"avgChangeRate":0.000626},{"month":10,"riseRate":0.2,"avgChangeRate":-0.082811},{"month":11,"riseRate":0.4,"avgChangeRate":0.029799},{"month":12,"riseRate":0.2,"avgChangeRate":-0.018114}],"exchange":"SEHK","name":"ZHAOKE OPHTH-B","nameEN":"ZHAOKE OPHTH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZHAOKE OPHTH-B(06622),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ZHAOKE OPHTH-B(06622) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ZHAOKE OPHTH-B,06622,ZHAOKE OPHTH-B股票,ZHAOKE OPHTH-B股票老虎,ZHAOKE OPHTH-B股票老虎国际,ZHAOKE OPHTH-B行情,ZHAOKE OPHTH-B股票行情,ZHAOKE OPHTH-B股价,ZHAOKE OPHTH-B股市,ZHAOKE OPHTH-B股票价格,ZHAOKE OPHTH-B股票交易,ZHAOKE OPHTH-B股票购买,ZHAOKE OPHTH-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZHAOKE OPHTH-B(06622),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ZHAOKE OPHTH-B(06622) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}